Abel Santos Carreira, Maria Queralt Salas, Mats Remberger, Igor Novitzky-Basso, Arjun Datt Law, Wilson Lam, Ivan Pasic, Tony Mazzulli, Christine Cserti-Gazdewich, Dennis Dong Hwan Kim, Fotios V Michelis, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Moustapha Hassan, Jonas Mattsson
This study investigates the incidence and predictors of hemorrhagic cystitis (HC) in 960 adults undergoing allo- hematopoietic stem cell transplantation. Two hundred fifty-two (26.5%) patients received myeloablative conditioning regimens, and 81.4% received high-dose intravenous busulfan (HD Bu). Six hundred ninety-five (72.4%) patients received post-transplantation cyclophosphamide (PTCY)-based prophylaxis, and 91.4% additionally received anti-thymocyte globulin (ATG) and Cyclosporine A (CsA) (PTCY-ATG-CsA)...
September 2023: Transplantation and cellular therapy